New oral GLP-1RA orforglipron comparable to semaglutide for weight loss
Results from the ACHIEVE-1 trial show that treatment with orforglipron was associated with weight loss ranging from 4.7 – 7.9% (4.4 – 7.3 Kg) of body weight in… read more.
Results from the ACHIEVE-1 trial show that treatment with orforglipron was associated with weight loss ranging from 4.7 – 7.9% (4.4 – 7.3 Kg) of body weight in… read more.
New results show Eli Lilly and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) at three years. These findings from the ADjoin… read more.
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about… read more.
Radiation from imaging could lead to lung, breast and other future cancers, with 10-fold increased risk for babies CT scans may account for 5% of all cancers annually,… read more.
A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the… read more.
Hydroxyurea therapy, a standard treatment for children with sickle cell disease (SCD), remains effective over the long term for reducing emergency department visits and hospital days among pediatric… read more.
The study, published in the journal Addiction and funded by Cancer Research UK, looked at survey data on vaping habits in England, Wales and Scotland before and after the UK… read more.
Prescribed burns literally fight fire with more fire. Often referred to as a “beneficial fire,” they target areas at risk for wildfires and burn away material that could… read more.
Complications during pregnancy (or adverse pregnancy outcomes), like gestational diabetes and newly developed high blood pressure, act as nature’s stress test and may uncover an individual’s risk for heart… read more.
PDS Biotechnology Corporation, a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel… read more.
NICE (UK): burosumab is recommended, within its marketing authorisation, for treating X‑linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in… read more.
Heart attack/myocardial infarction (MI) patients treated early with cholesterol-lowering ezetimibe and a statin have achieved a significantly better prognosis than those who received ezetimibe later or not all…. read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.